- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07641764
3D Printed vs Ready-to-Wear Insoles for Diabetic Neuropathy (3DP-DPN)
14 juni 2026 uppdaterad av: Anbreena Rasool, University of Faisalabad
Comparative Effect of 3D Printed Customized Insoles and Ready to Wear Insoles on Plantar Pressure Changes in Patients With Diabetic Neuropathy
Diabetic neuropathy is a condition caused by chronic high blood glucose levels that damage nerves over time, frequently causing abnormal plantar pressure and increasing the risk of foot ulcers and impaired mobility.
Insoles are widely used to redistribute pressure and improve comfort.
This study compares the effect of 3D printed customized insoles versus ready-to-wear insoles on plantar pressure changes in patients with diabetic neuropathy.
The study is a randomized controlled trial with 22 participants randomly allocated to two groups: one receiving 3D printed customized insoles and the other receiving ready-to-wear insoles.
Plantar pressure is measured using piezoresistive sensors and an Arduino Nano Unit.
Secondary outcomes include foot health status (FSHQ questionnaire), satisfaction with assistive technology (QUEST 2.0), and neuropathy severity (NSS and NDS questionnaires).
Assessments occur at baseline, 4 weeks, and 8 weeks.
Studieöversikt
Status
Aktiv, inte rekryterande
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This is a single-blind, parallel-group randomized controlled trial conducted at DHQ-1 and DHQ-2 hospitals in Okara, Pakistan.
Participants are adults aged 35-65 years with diagnosed diabetic neuropathy who can walk independently without aids.
Exclusion criteria include foot ulcers, external wounds, recent surgery, major limb amputation, foot drop, peripheral vascular disease, neuromuscular diseases, and Charcot arthropathy.
A consecutive sampling technique is used to recruit 22 participants.
Randomization is performed using a computer-generated sequence.
Participants are blinded to their group allocation.
Group A receives 3D printed customized insoles tailored to individual foot morphology using 3D scanning and printing technology.
These insoles provide arch support and gait alignment.
Group B receives ready-to-wear insoles providing general cushioning and basic support.
Both groups follow an 8-week intervention protocol: participants wear insoles for a minimum of 6 hours per day, 5 days per week, and perform level walking on a 28-meter pathway at self-selected speed.
The protocol is divided into phases: weeks 1-2 for acclimatization and footwear assessment using Semmes-Weinstein 10g monofilament; weeks 3-4 for pressure adaptation and skin monitoring; weeks 5-6 for enhanced foot function and balance improvement; weeks 7-8 for final assessment.
Primary outcome: plantar pressure measured via piezoresistive sensors and Arduino Nano Unit.
Secondary outcomes: Foot Health Status Questionnaire (FSHQ), Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0), Neuropathy Symptom Score (NSS), and Neuropathy Deficit Score (NDS).
Data are collected at baseline, week 4, and week 8. Statistical analysis uses SPSS version 22.
Studietyp
Interventionell
Inskrivning (Beräknad)
22
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
Punjab Province
-
Faisalābad, Punjab Province, Pakistan, 3800
- The University of Faisalabad
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Nej
Beskrivning
Inclusion Criteria:
- Age 35 to 65 years
- Diagnosed with diabetes mellitus
- Clinical diagnosis of diabetic peripheral neuropathy
- Ability to walk independently without walking aids
- Normal cognitive function
- Corrected or uncorrected vision sufficient for safe ambulation
- Willingness to provide written informed consent
Exclusion Criteria:
- Presence of active foot ulcer
- External wound on lower extremity
- History of lower limb surgery within past 6 months
- Major lower limb amputation
- Foot drop
- Peripheral vascular disease
- Neuromuscular diseases (e.g., stroke, Parkinson's disease, multiple sclerosis)
- Charcot arthropathy
- Inability to comply with study protocol
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Group A: 3D Printed Customized Insoles
Participants in this group receive 3D printed customized insoles tailored to individual foot morphology.
Insoles are designed to provide arch support and gait alignment.
Participants wear insoles for minimum 6 hours/day, 5 days/week for 8 weeks, following a phased protocol of acclimatization, pressure adaptation, and function improvement.
|
3D printed customized insoles are fabricated using 3D scanning of the participant's foot to capture individual morphology.
The insoles are printed using thermoplastic polyurethane (TPU) or similar 3D printing filament.
The intervention involves daily wear of insoles for minimum 6 hours per day, 5 days per week, for 8 weeks.
Participants perform level walking on a 28-meter pathway at self-selected speed.
Weekly assessments monitor adherence, skin condition, and comfort.
Patient education on foot care and insole use is provided.
Ready-to-wear insoles are prefabricated insoles providing general cushioning and shock absorption.
These insoles are not customized to individual foot morphology.
The intervention involves daily wear of insoles for minimum 6 hours per day, 5 days per week, for 8 weeks.
Participants perform level walking on a 28-meter pathway at self-selected speed.
Weekly assessments monitor adherence, skin condition, and comfort.
Patient education on foot care and insole use is provided.
|
|
Aktiv komparator: Group B: Ready-to-Wear Insoles
Participants in this group receive prefabricated ready-to-wear insoles providing general cushioning and basic support.
Participants wear insoles for minimum 6 hours/day, 5 days/week for 8 weeks, following the same phased protocol as the experimental group.
|
Ready-to-wear insoles are prefabricated insoles providing general cushioning and shock absorption.
These insoles are not customized to individual foot morphology.
The intervention involves daily wear of insoles for minimum 6 hours per day, 5 days per week, for 8 weeks.
Participants perform level walking on a 28-meter pathway at self-selected speed.
Weekly assessments monitor adherence, skin condition, and comfort.
Patient education on foot care and insole use is provided.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in Plantar Pressure Distribution
Tidsram: Baseline (Week 0), Mid-intervention (Week 4), Post-intervention (Week 8)
|
Plantar pressure is measured using piezoresistive sensors connected to an Arduino Nano Unit.
Participants walk barefoot across the sensor platform.
The sensor records pressure distribution across the plantar surface in kilopascals (kPa).
Higher pressure values indicate greater plantar load, which is associated with increased risk of foot ulceration.
Lower pressure values indicate better offloading.
|
Baseline (Week 0), Mid-intervention (Week 4), Post-intervention (Week 8)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Foot Health Status Questionnaire (FSHQ) Score
Tidsram: Baseline (Week 0), Week 4, Week 8
|
The Foot Health Status Questionnaire (FSHQ) is a validated instrument assessing foot-related quality of life.
It includes domains of foot pain, foot function, footwear, and general foot health.
Each item is scored on a Likert scale.
Minimum score is zero and maximum score is 100.
scores are generally classified into ranges such as Very Low: 0-24.9
Low:25-49.9
Medium: 50-74.9
High: 75-100 HIgher score indicates better foot health and lower score indicates worst foot health.
|
Baseline (Week 0), Week 4, Week 8
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
1 januari 2026
Primärt slutförande (Beräknad)
30 juni 2026
Avslutad studie (Beräknad)
15 juli 2026
Studieregistreringsdatum
Först inskickad
6 juni 2026
Först inskickad som uppfyllde QC-kriterierna
6 juni 2026
Första postat (Faktisk)
11 juni 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
17 juni 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
14 juni 2026
Senast verifierad
1 juni 2026
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Sjukdomar i det endokrina systemet
- Sjukdomar i nervsystemet
- Kärlsjukdomar
- Hjärt-kärlsjukdomar
- Neuromuskulära sjukdomar
- Sjukdomar i det perifera nervsystemet
- Diabetes mellitus
- Diabetiska angiopatier
- Diabeteskomplikationer
- Hudsjukdomar
- Hudsår
- Bensår
- Fotsår
- Hud- och bindvävssjukdomar
- Diabetiska neuropatier
- Diabetesfot
Andra studie-ID-nummer
- TUF/EIRB/ 195 /26
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
NEJ
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .